Acquiring Convalescent Specimens for COVID-19 Antibodies

Completed

Conditions studied: COVID-19, Coronavirus Infection, Corona Virus Infection

In brief

Blood samples from participants who have recovered from COVID-19 infection will be obtained and studied. The goal of the research is to identify antibodies that have been generated by the patient to fight the COVID-19 infection. By identifying the most effective antibodies, scientists can make specific antibodies to use to prevent future coronavirus outbreaks or to treat patients with severe disease.

Key facts

Study ID

NCT04342195

Run by

Columbia University

People needed

15

Starts

2020-03-25

Expected to finish

2021-03-12

Last updated by the study team

2022-07-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 to 65 (inclusive)
• Confirmed COVID-19 infection by a FDA-approved molecular based assay (including those under emergency use authorization) of respiratory or blood specimens;
• If symptomatic with COVID-19, must have evidence of improvement of symptoms and a duration of at least 4 weeks from the onset of symptoms to day of enrollment;
• If asymptomatic, must have a duration of at least 4 weeks from first positive molecular based COVID-19 assay to day of enrollment

You may not qualify if…

• <18 years or >65 years old
• No confirmed diagnosis of COVID-19

Where it is running

• Columbia University Irving Medical Center/NYP — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.